Tag Archives: Replimune

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we talk about the midsummer chill in the biotech market here in my home town of San Diego. Also, we learn that it was FDA cancer chief Richard Pazdur’s intervention that contributed to the rejection of Replimune’s melanoma drug …

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. The top regulator of cancer drugs at the Food and …